NLS Agreement

Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and commercialization rights, excluding the Greater China area (mainland China, Hong Kong, Macau and Taiwan), for a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain. Orion will also receive ownership to […]

BioArctic has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805. BioArctic and AbbVie have collaborated since 2016 regarding the research and development of BioArctic’s portfolio of alpha-synuclein antibodies for Parkinson’s disease and other potential indications. In 2019, a Phase 1 study […]

Idogen has signed a strategic collaboration agreement with two contract research organizations, Danish Klifo and Finnish 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8. IDO 8 is a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The […]

Finnish DelSiTech and Swiss-based Optifye Therapeutics have announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech Silica Matrix technology. Controlled release of dexamethasone eye drops, based on DelSiTech Silica Matrix technology, is an eye drop product that is applied as a single drop, once daily under the eye […]

The companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of clinical material for Oasmia’s investigational drug candidate, Cantrixil. “We are excited to have partnered with Lonza, a global leader in drug manufacturing. The manufacture of Cantrixil is planned to be performed in three steps and this agreement is […]

Bavarian Nordic has entered into an exclusive license and supply agreement with Nuance Pharma, a Shanghai-based specialty pharmaceutical company. The agreement concerns the development and commercialization of MVA-BN RSV against respiratory syncytial virus (RSV) in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries. The agreement entails clinical development, […]